Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 79,327 shares of Crispr Therapeutics stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $18.89, for a total value of $1,498,487.03. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total value of $172,800.00.

Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.01 during midday trading on Thursday, hitting $18.53. The stock had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a 12 month low of $11.63 and a 12 month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. During the same period last year, the firm posted ($2.77) EPS. The company’s revenue was up 54.2% on a year-over-year basis. analysts expect that Crispr Therapeutics AG will post -2.46 earnings per share for the current year.

CRSP has been the subject of several research analyst reports. Chardan Capital reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Barclays reaffirmed a “buy” rating and set a $29.00 price target on shares of Crispr Therapeutics in a research note on Friday, September 8th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Finally, SunTrust Banks reissued a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $22.38.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Credit Suisse AG bought a new position in Crispr Therapeutics during the 1st quarter valued at approximately $1,742,000. Wells Fargo & Company MN raised its position in Crispr Therapeutics by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares during the last quarter. Vanguard Group Inc. bought a new position in Crispr Therapeutics during the 2nd quarter valued at approximately $273,000. Ark Investment Management LLC bought a new position in Crispr Therapeutics during the 2nd quarter valued at approximately $206,000. Finally, Moloney Securities Asset Management LLC bought a new position in Crispr Therapeutics during the 3rd quarter valued at approximately $235,000. 24.55% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Corp /De/ Celgene Sells 79,327 Shares of Crispr Therapeutics AG (CRSP) Stock” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/07/corp-de-celgene-sells-79327-shares-of-crispr-therapeutics-ag-crsp-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.